RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
肿瘤免疫治疗中的 CD24 靶向
英文原题：Targeting CD24 in Cancer Immunotherapy.
查看英文原题
Targeting CD24 in Cancer Immunotherapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
免疫治疗是癌症治疗的热点领域，而该疗法的关键之一在于识别正确的肿瘤相关抗原或肿瘤特异性抗原。分化簇24（CD24）是一种新兴的肿瘤相关抗原，在多种肿瘤中普遍高表达。此外，CD24与多条癌症相关信号通路相关，并与其他分子和免疫细胞密切相互作用，影响肿瘤进展。目前可用于靶向CD24治疗的手段包括单克隆抗体、抗体药物偶联物（ADC）、嵌合抗原受体（CAR）T细胞疗法和CAR-NK细胞疗法。在本综述中，我们总结了现有的治疗策略以及靶向CD24可能的未来方向。
展开英文摘要原文
Immunotherapy is a hot area in cancer treatment, and one of the keys to this therapy is the identification of the right tumour-associated or tumour-specific antigen. Cluster of differentiation 24 (CD24) is an emerging tumour-associated antigen that is commonly and highly expressed in various tumours.
In addition, CD24 is associated with several cancer-related signalling pathways and closely interacts with other molecules and immune cells to influence tumour progression. Monoclonal antibodies, antibody-drug conjugates (ADCs), chimeric antigen receptor (CAR) T-cell therapy, and CAR-NK cell therapy are currently available for the treatment of CD24. In this review, we summarise the existing therapeutic approaches and possible future directions targeting CD24.
论文信息
- 作者
- Chen W、Hu Z、Guo Z
- 单位
- Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences, Nanjing Normal University, 1 Wenyuan Road, Nanjing 210023, China.China
- 文献类型
- 综述
- 期刊
- Biomedicines2023 Nov 27
- 原文标识
- PubMed 38137380 · DOI 10.3390/biomedicines11123159
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →